Search | Engineering

Subscribe Submit

Home Journals Focus Achievement Fronts About Us 中文版

Resource Type

Journal Article 2

Year

2016 1

2008 1

Keywords

Chinese patients 1

JAK 1

JAK2V617F detection 1

JAK2V617F-positive 1

Single-tube bi-directional 1

essential thrombocythemia 1

myelofibrosis 1

ruxolitinib 1

specific amplification 1

open ︾

Search scope:

排序： Display mode:

Efficacy and safety of JAK inhibitor INC424 in patients with primary and post-polycythemia vera or post-essential

Xin Du,Daobin Zhou

Frontiers of Medicine 2016, Volume 10, Issue 4, Pages 437-443 doi: 10.1007/s11684-016-0472-9

Abstract:

A phase II study (A2202) was performed to evaluate the efficacy and safety of JAK inhibitor ruxolitinib

Keywords： JAK ruxolitinib Chinese patients myelofibrosis

HTML PDF Collect

Observation of a higher JAK2 V617F homozygous mutated clone in polycythemia vera compared to essential

LIU Hongxing, TONG Chunrong, CAI Peng, GU Jiangying, LIN Yuehui, TENG Wen, WANG He, ZHANG Ying, ZHU Ping

Frontiers of Medicine 2008, Volume 2, Issue 3, Pages 309-313 doi: 10.1007/s11684-008-0059-1

Abstract: and real-time quantitative polymerase chain reaction (RQ-PCR) assays were developed and performed for JAK2V617FThe results showed that in some samples, the JAK2V617F burden was as low as nearly 1%, and thus moreJAK2V617F-positive samples were detected by RQ-PCR than by SB-ASA assay due to the former higher detectOur result shows that the pathogenesis of PV and ET may be related to the mutation allele burden of JAK2V617F

Keywords： specific amplification essential thrombocythemia Single-tube bi-directional JAK2V617F-positive JAK2V617F